CN103748142B - 可逆交联的胶束系统 - Google Patents

可逆交联的胶束系统 Download PDF

Info

Publication number
CN103748142B
CN103748142B CN201280032611.3A CN201280032611A CN103748142B CN 103748142 B CN103748142 B CN 103748142B CN 201280032611 A CN201280032611 A CN 201280032611A CN 103748142 B CN103748142 B CN 103748142B
Authority
CN
China
Prior art keywords
acid
peg
group
nano
ptx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280032611.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103748142A (zh
Inventor
基特·S·拉姆
李源培
罗君涛
肖凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN103748142A publication Critical patent/CN103748142A/zh
Application granted granted Critical
Publication of CN103748142B publication Critical patent/CN103748142B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
CN201280032611.3A 2011-05-13 2012-05-14 可逆交联的胶束系统 Active CN103748142B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485774P 2011-05-13 2011-05-13
US61/485,774 2011-05-13
US201161487953P 2011-05-19 2011-05-19
US61/487,953 2011-05-19
PCT/US2012/037794 WO2012158622A2 (en) 2011-05-13 2012-05-14 Reversibly crosslinked micelle systems

Publications (2)

Publication Number Publication Date
CN103748142A CN103748142A (zh) 2014-04-23
CN103748142B true CN103748142B (zh) 2016-04-27

Family

ID=47177586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280032611.3A Active CN103748142B (zh) 2011-05-13 2012-05-14 可逆交联的胶束系统

Country Status (5)

Country Link
US (2) US10106650B2 (enExample)
EP (1) EP2707419B1 (enExample)
JP (1) JP6542827B2 (enExample)
CN (1) CN103748142B (enExample)
WO (1) WO2012158622A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110392583A (zh) * 2016-09-15 2019-10-29 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2915692T3 (es) 2008-08-13 2022-06-24 California Inst Of Techn Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
EP2707419B1 (en) 2011-05-13 2019-08-14 The Regents of The University of California Reversibly crosslinked micelle systems
HK1198628A1 (en) * 2011-08-12 2015-05-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
CN104105508B (zh) 2011-12-21 2017-10-24 加利福尼亚大学董事会 药物递送增强的末端树枝状聚合物
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
ES2986545T3 (es) * 2013-03-01 2024-11-11 California Inst Of Techn Nanopartículas dirigidas
EP2961788B1 (en) * 2013-03-01 2019-05-08 California Institute of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
CN104414973A (zh) * 2013-08-21 2015-03-18 复旦大学 一种视黄酸和紫杉醇共递药的胶束给药系统及其制备方法
US11406714B2 (en) 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
CN105193732A (zh) * 2014-06-05 2015-12-30 华东理工大学 雷帕霉素纳米缓释微球及其制备方法
CN104530413B (zh) * 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
WO2016050208A1 (zh) * 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物修饰的生物相关物质
WO2016050210A1 (zh) * 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104530417B (zh) * 2014-10-01 2017-09-08 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物及其制备方法
WO2016057657A1 (en) * 2014-10-07 2016-04-14 The Research Foundation For The State University Of New York Functional segregated telodendrimers and nanocarriers and methods of making and using same
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
ES2625024B1 (es) * 2015-12-18 2018-05-10 Consejo Superior De Investigaciones Cientificas Material que comprende tectómeros de oligoglicina y nanohilos
CN109562078A (zh) * 2016-03-03 2019-04-02 特瑞奥纳米有限公司 多药物复合物、其制备方法及用途
US10517823B1 (en) 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10583083B1 (en) * 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
WO2018136778A1 (en) 2017-01-19 2018-07-26 The Research Foundation For The State University Of New York Telodendrimers with riboflavin moieties and nanocarriers and methods of making and using same
JP2018058868A (ja) * 2017-11-24 2018-04-12 カリフォルニア インスティテュート オブ テクノロジー ニトロフェニルボロン酸組成物によって安定化したナノ粒子
JP2018070626A (ja) * 2017-11-24 2018-05-10 カリフォルニア インスティテュート オブ テクノロジー 標的化ナノ粒子
JP7525981B2 (ja) * 2017-11-24 2024-07-31 カリフォルニア インスティテュート オブ テクノロジー ニトロフェニルボロン酸組成物によって安定化したナノ粒子
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN112584867B (zh) * 2018-08-13 2024-12-13 聚合物工厂瑞典公司 树枝状纳米凝胶载体及其生产方法
US12527880B2 (en) 2018-08-31 2026-01-20 The Regents Of The University Of California Cyanine-based telodendrimers and uses for treating cancer
CN111184874B (zh) * 2018-11-14 2022-02-22 南京大学 疏水性纳米生物探针
US11179475B2 (en) 2018-11-28 2021-11-23 International Business Machines Corporation Biodegradable functional polycarbonate nanoparticle carries for delivering molecular cargo
JP2019108371A (ja) * 2019-03-04 2019-07-04 カリフォルニア インスティテュート オブ テクノロジー 標的化ナノ粒子
CN111904932B (zh) * 2019-05-08 2023-06-20 北京德立福瑞医药科技有限公司 一种含有糖皮质激素的胶束制剂及其制备方法
WO2021113643A2 (en) 2019-12-04 2021-06-10 Dantari, Inc. Methods and compositions for synthesis of therapeutic nanoparticles
US20230076792A1 (en) * 2019-12-17 2023-03-09 The Regents Of The University Of California Sequential targeting in crosslinking nano-theranostics for treating brain tumors
EP4429798A4 (en) * 2021-11-09 2026-01-21 Massachusetts Inst Technology PARTICLES CONTAINING POLLUTANT CAPTURE MICELLES AND ASSOCIATED PROCESSES
EP4460313A4 (en) * 2022-01-04 2026-01-14 Univ New York State Res Found CMT-3 FORMULATIONS AND THEIR METHODS OF USE
CN115531291B (zh) * 2022-09-02 2025-02-14 南京医科大学 一种可载药的赖氨大黄酸自组装水凝胶及其制备方法与应用
WO2024254448A2 (en) * 2023-06-07 2024-12-12 The Research Foundation For The State University Of New York Boronate prodrug nanoformulations in disease treatments
CN121064464B (zh) * 2025-11-06 2026-02-24 北京师范大学珠海校区 一种基于天然分子胆酸的抗菌牙科树脂材料

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039496A2 (en) * 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009133A1 (fr) 1998-08-10 2000-02-24 Asahi Kasei Kogyo Kabushiki Kaisha Preparations orales, a liberation prolongee, a base de chlorhydrate de fasudil
JP4659937B2 (ja) 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US7846893B2 (en) 2005-02-16 2010-12-07 Rutgers, The State University Of New Jersey Drug-polymer conjugates coupled to a peptidic carrier
US8153110B2 (en) 2006-11-22 2012-04-10 The University Of Tokyo Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle
US9296988B2 (en) 2009-06-19 2016-03-29 The Regents Of The University Of California Three-dimensional cell adhesion matrix
EP2707419B1 (en) 2011-05-13 2019-08-14 The Regents of The University of California Reversibly crosslinked micelle systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039496A2 (en) * 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Disulfide-Crosslinked Polyion Micelles for Delivery of Protein Therapeutics;MICHAEL J. HEFFERNAN et al.;《Annals of Biomedical Engineering》;20090610;1993-2002 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110392583A (zh) * 2016-09-15 2019-10-29 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物
CN110392583B (zh) * 2016-09-15 2023-01-03 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物

Also Published As

Publication number Publication date
JP6542827B2 (ja) 2019-07-10
US11192978B2 (en) 2021-12-07
US20150045419A1 (en) 2015-02-12
CN103748142A (zh) 2014-04-23
JP6235460B2 (ja) 2017-11-22
EP2707419A4 (en) 2014-11-26
WO2012158622A2 (en) 2012-11-22
JP2014514431A (ja) 2014-06-19
US10106650B2 (en) 2018-10-23
EP2707419A2 (en) 2014-03-19
JP2017149960A (ja) 2017-08-31
WO2012158622A3 (en) 2013-03-28
US20190112423A1 (en) 2019-04-18
EP2707419B1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
US11192978B2 (en) Reversibly crosslinked micelle systems
CN104105508B (zh) 药物递送增强的末端树枝状聚合物
CN102159189B (zh) 用于药物递送的纳米载体
US9642916B2 (en) Porphyrin modified telodendrimers
EP3035968B1 (en) Telodendrimers and nanocarriers and methods of using same
JP7102005B2 (ja) 改善されたハイブリッドテロデンドリマー
JP6235460B6 (ja) 可逆的に架橋されたミセルｓｙｓｔｅｍｓ

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant